NMI Stock Overview
Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Aladdin Healthcare Technologies SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0015 |
| 52 Week High | €0.01 |
| 52 Week Low | €0.001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -50.00% |
| 3 Year Change | -99.64% |
| 5 Year Change | -99.99% |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| NMI | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | 1.7% |
| 1Y | -50.0% | -24.3% | 2.3% |
Price Volatility
| NMI volatility | |
|---|---|
| NMI Average Weekly Movement | 35.4% |
| Healthcare Services Industry Average Movement | 3.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Wade Menpes-Smith | www.aladdinid.com |
Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. The company provides Artificial Intelligence assisted Drug Discovery platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer’s, Parkinson's, and SARS-CoV-2; PharmaKG, a biomedical knowledge graph; and Disease Diagnosis and Risk Assessment Platform. The company was founded in 2014 and is based in Berlin, Germany.
Aladdin Healthcare Technologies SE Fundamentals Summary
| NMI fundamental statistics | |
|---|---|
| Market cap | €17.19k |
| Earnings (TTM) | €12.35k |
| Revenue (TTM) | €490.42k |
0.0x
P/E Ratio0.0x
P/S RatioIs NMI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NMI income statement (TTM) | |
|---|---|
| Revenue | €490.42k |
| Cost of Revenue | €190.13k |
| Gross Profit | €300.29k |
| Other Expenses | €287.94k |
| Earnings | €12.35k |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NMI perform over the long term?
See historical performance and comparison